Session II: Cancer of the Pancreas and Biliary Tract

SO-2: Pancreatic Cancer in HIV versus Non-HIV population – Analysis of Demographics, Outcomes and Healthcare Utilization from a national sample

Syed Ali Amir Sherazi

The study authors demonstrate that pancreatic cancer occurred at a significantly younger age in HIV-PC patients compared to non-HIV-PC patients. Racial disparity followed the same trend as general HIV infection. Adjusted mortality was lower in HIV-PC while most medical comorbidities, secondary outcomes, and adjusted healthcare utilization were not significantly different between HIV and non-HIV groups with PC. HIV-positive status does not add significantly to the medical burden in patients with pancreatic cancer.

LBA-1: Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

Margaret A. Tempero

The study authors conclude that the 5-year overall survival outcomes in the APACT trial were consistent with those observed in both the primary analysis and the prior post hoc updated analysis for nab-paclitaxel + gemcitabine versus gemcitabine alone. Although APACT did not meet its primary endpoint of independently assessed disease-free survival in the primary analysis, according to the authors, this overall survival data suggest improved outcomes with nab-paclitaxel + gemcitabine.


SO-3: Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

Julien Taieb

The study authors conclude that their large real-life study highlighted a clear picture of treatment sequences (first line followed by a second line) in European real-world clinical practice and outcomes for patients with mPAC. They note, that treatment sequences were in accordance with the ESMO guidelines at the time of the study. Liver metastases, treatment sequences, PS, CA19-9, lung metastases, and sex were significant independent prognostic factors of OS in this study.


SO-4: Progression-free Survival in Patients With Cholangiocarcinoma With FGFR2 Fusions or Rearrangements: A FIGHT-202 Post-hoc Analysis of Prior Systemic Therapy Response

Ghassan K. Abou-Alfa

The study authors conclude that their post-hoc analysis provides data about progression-free survival (PFS) on standard systemic therapies received before pemigatinib for patients with FGFR2+ Cholangiocarcinoma (CCA). They further conclude that the short PFS on these standard therapies in patients with FGFR2+ CCA highlights the need for the development of other options including targeted therapies to improve outcomes. Median PFS on second- or third-line pemigatinib for FGFR2+ CCA was longer than second- or third-line systemic therapy received prior to FIGHT-202 enrollment.